BONS Stock Overview
A clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bonus BioGroup Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.091 |
| 52 Week High | ₪0.32 |
| 52 Week Low | ₪0.09 |
| Beta | 1.05 |
| 1 Month Change | -22.88% |
| 3 Month Change | -30.00% |
| 1 Year Change | -45.51% |
| 3 Year Change | -92.02% |
| 5 Year Change | -78.44% |
| Change since IPO | -62.08% |
Recent News & Updates
We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate
Apr 01
Will Bonus BioGroup (TLV:BONS) Spend Its Cash Wisely?
Dec 11We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate
Jun 14Recent updates
We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate
Apr 01Will Bonus BioGroup (TLV:BONS) Spend Its Cash Wisely?
Dec 11We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate
Jun 14Is Bonus BioGroup (TLV:BONS) In A Good Position To Deliver On Growth Plans?
Dec 13Companies Like Bonus BioGroup (TLV:BONS) Are In A Position To Invest In Growth
Jun 26Here's Why We're Not Too Worried About Bonus BioGroup's (TLV:BONS) Cash Burn Situation
Jan 28Here's Why We're Not Too Worried About Bonus BioGroup's (TLV:BONS) Cash Burn Situation
Sep 15Here's What Bonus BioGroup Ltd.'s (TLV:BONS) Shareholder Ownership Structure Looks Like
Mar 05What Kind Of Investors Own Most Of Bonus BioGroup Ltd. (TLV:BONS)?
Nov 19Shareholder Returns
| BONS | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | -15.0% | -3.4% | 0.2% |
| 1Y | -45.5% | -26.4% | 23.2% |
Return vs Industry: BONS underperformed the IL Biotechs industry which returned -26.6% over the past year.
Return vs Market: BONS underperformed the IL Market which returned 25.5% over the past year.
Price Volatility
| BONS volatility | |
|---|---|
| BONS Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IL Market | 8.0% |
| 10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: BONS has not had significant price volatility in the past 3 months compared to the IL market.
Volatility Over Time: BONS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 58 | Shai Meretzki | bonus-bio.com |
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company’s products in development include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications and is in Phase II clinical trial; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS and is in phase III trial. Its products in pipeline also comprise BonoFill for bone augmentation in osteoporosis patients; MesenCure for treating other inflammations and tissue damage; vascularized bone grafts; and soft tissue grafts.
Bonus BioGroup Ltd. Fundamentals Summary
| BONS fundamental statistics | |
|---|---|
| Market cap | ₪106.28m |
| Earnings (TTM) | -₪29.47m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.6x
P/E RatioIs BONS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BONS income statement (TTM) | |
|---|---|
| Revenue | ₪0 |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪0 |
| Other Expenses | ₪29.47m |
| Earnings | -₪29.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BONS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 14:05 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bonus BioGroup Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|